BCAB
NASDAQBioAtla Inc.
Website
News25/Ratings8
News · 26 weeks44-45%
2025-10-262026-04-19
Mix2290d
- SEC Filings11(50%)
- Insider7(32%)
- Other3(14%)
- Earnings1(5%)
Latest news
25 items- SECBioAtla Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - BioAtla, Inc. (0001826892) (Filer)
- SECSEC Form S-8 filed by BioAtla Inc.S-8 - BioAtla, Inc. (0001826892) (Filer)
- SECBioAtla Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - BioAtla, Inc. (0001826892) (Filer)
- SECSEC Form 10-K filed by BioAtla Inc.10-K - BioAtla, Inc. (0001826892) (Filer)
- PRBioAtla Announces Share ConsolidationSAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it will effect a 50-for-1 share consolidation (the "Share Consolidation") of its common stock, par value $0.0001 per share (the "Common Stock"), that is expected to become effective on April 6, 2026 at 12:01 a.m. Eastern Time (the "Effective Date"). The Common Stock will continue to trade on The Nasdaq Capital Market under the existing symbol "BCAB" and is expected to begin trading on a split-adjusted basis when the market opens
- PRBioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business HighlightsInitiated a formal process to monetize assets Implemented a restructuring plan to significantly reduce operating expenses and extend runway SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced its financial results for the full year and fourth quarter ended December 31, 2025 and provided business highlights. "As we evaluate strategic paths forward, our focus remains on supporting the advancement of the ongoing Phase 1 study of BA3182 in adenocarcinomas, while preserving capital, and e
- SECBioAtla Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders8-K - BioAtla, Inc. (0001826892) (Filer)
- INSIDERChief Medical Officer Sievers Eric was granted 240,000 shares, increasing direct ownership by 67% to 598,705 units (SEC Form 4)4 - BioAtla, Inc. (0001826892) (Issuer)
- INSIDERChief Executive Officer Short Jay M Phd was granted 430,000 shares, increasing direct ownership by 19% to 2,659,603 units (SEC Form 4)4 - BioAtla, Inc. (0001826892) (Issuer)
- INSIDERChief Financial Officer Vasquez Christian was granted 240,000 shares, increasing direct ownership by 83% to 530,196 units (SEC Form 4)4 - BioAtla, Inc. (0001826892) (Issuer)
- INSIDERChief Executive Officer Short Jay M Phd covered exercise/tax liability with 7,728 shares, decreasing direct ownership by 0.35% to 2,229,603 units (SEC Form 4)4 - BioAtla, Inc. (0001826892) (Issuer)
- INSIDERChief Financial Officer Vasquez Christian covered exercise/tax liability with 1,802 shares, decreasing direct ownership by 0.62% to 290,196 units (SEC Form 4)4 - BioAtla, Inc. (0001826892) (Issuer)
- INSIDERFormer Chief Financial Officer Waldron Richard A covered exercise/tax liability with 2,729 shares, decreasing direct ownership by 0.79% to 343,421 units (SEC Form 4)4 - BioAtla, Inc. (0001826892) (Issuer)
- INSIDERChief Medical Officer Sievers Eric covered exercise/tax liability with 3,140 shares, decreasing direct ownership by 0.87% to 358,705 units (SEC Form 4)4 - BioAtla, Inc. (0001826892) (Issuer)
- SECSEC Form DEFA14A filed by BioAtla Inc.DEFA14A - BioAtla, Inc. (0001826892) (Filer)
- SECBioAtla Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Costs Associated with Exit or Disposal Activities, Leadership Update, Other Events, Financial Statements and Exhibits8-K - BioAtla, Inc. (0001826892) (Filer)
- PRBioAtla Announces Formal Process to Evaluate Strategic Options to Monetize AssetsSAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, announced that the Board of Directors has initiated a formal process to explore and evaluate strategic options to maximize shareholder value, including the sale of preclinical and clinical assets, licensing transactions, strategic partnerships or other corporate transactions. Concurrently, the Company is implementing a restructuring plan to significantly reduce operating expenses, including a workforce reduction of approximately 70% and expansion of
- SECSEC Form DEFM14A filed by BioAtla Inc.DEFM14A - BioAtla, Inc. (0001826892) (Filer)
- SECSEC Form 8-K filed by BioAtla Inc.8-K - BioAtla, Inc. (0001826892) (Filer)
- SECBioAtla Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure8-K - BioAtla, Inc. (0001826892) (Filer)
- SECSEC Form PREM14A filed by BioAtla Inc.PREM14A - BioAtla, Inc. (0001826892) (Filer)
- SECBioAtla Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - BioAtla, Inc. (0001826892) (Filer)
- SECSEC Form S-3 filed by BioAtla Inc.S-3 - BioAtla, Inc. (0001826892) (Filer)
- SECSEC Form DEFA14A filed by BioAtla Inc.DEFA14A - BioAtla, Inc. (0001826892) (Filer)
- ANALYSTRodman & Renshaw initiated coverage on BioAtla with a new price targetRodman & Renshaw initiated coverage of BioAtla with a rating of Buy and set a new price target of $4.00